HBV Approval Gives Viread A Needed Boost
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. clearance follows nod from European regulators.
You may also be interested in...
As It Prepares for a Future with Wyeth, Pfizer Reports Ho-Hum Q1 Results
Pfizer’s first-quarter results were down, but in line with the company’s and Wall Street’s expectations.
Gilead’s Viread In HBV Shores Up Flagging Sales For Drug In HIV
Analyst suggests $300 million additional revenue from Viread’s HBV indication.
Gilead’s Viread In HBV Shores Up Flagging Sales For Drug In HIV
Analyst suggests $300 million additional revenue from Viread’s HBV indication.